Skip to main content
. 2022 Aug 8;8:e2100380. doi: 10.1200/GO.21.00380

FIG 3.

FIG 3

PFS of patients with Waldenstrom Macroglobulinemia according to (A) treatment IPSSWM score, (B) sex, (C) rituximab use, and (D) type of treating institution. IPSSWM, International Prognostic Scoring System for WM; PFS, progression-free survival.